| Property | Value |
|
has major subject area list
|
COVID-19; COVID-19 Vaccines; Hospitalization; SARS-CoV-2; Vaccine Efficacy
|
|
information resource reference
|
DeCuir J, Surie D, Zhu Y, Lauring AS, Gaglani M, McNeal T, Ghamande S, Peltan ID, Brown SM, Ginde AA, Steinwand A, Mohr NM, Gibbs KW, Hager DN, Ali H, Frosch A, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Khan A, Busse LW, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Exline MC, Shapiro NI, Columbus C, Vaughn IA, Ramesh M, Safdar B, Mosier JM, Casey JD, Talbot HK, Rice TW, Halasa N, Chappell JD, Grijalva CG, Baughman A, Womack KN, Rhoads JP, Swan SA, Johnson C, Lewis N, Ellington S, Dawood FS, McMorrow M, Self WH. Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023. Influenza Other Respir Viruses. 2024 11; 18(11):e70027.
|
|
label
|
Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023.
|